Insulin degludec is a new ultra-long-acting insulin analogue
Achieving optimal glycemic control is an important aspect of preventing and slowing the progression of diabetes-associated complications, and reducing the cost of their treatment. Long-acting insulin analogues, glargine and detemir, provide better metabolic control with reduced risk of hypoglycaemia...
Guardado en:
Autores principales: | Ivan Ivanovich Dedov, Marina Vladimirovna Shestakova |
---|---|
Formato: | article |
Lenguaje: | EN RU |
Publicado: |
Endocrinology Research Centre
2014
|
Materias: | |
Acceso en línea: | https://doaj.org/article/6e417b1bfcf04a568b284fe7ce6e9f5f |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Insulin degludec/insulin aspart is the first co-formulation of basal and prandial insulin analogues
por: Ivan Ivanovich Dedov, et al.
Publicado: (2014) -
Data on the first experience of insulin degludec (Tresiba®) treatment for type 2 diabetes in daily clinical practice
por: Lyudmila Alexandrovna Suplotova, et al.
Publicado: (2015) -
Modern basal insulins: an ongoing story or the start of a new era?
por: Ivan Ivanovich Dedov
Publicado: (2015) -
National advisory board on diabetes mellitus: unsolved issues and new opportunities for diabetes treatment
por: Gagik Radikovich Galstyan
Publicado: (2014) -
The first and only combination of basal and prandial insulin analogs degludec and aspart: the position of Russian endocrinologists
por: M. V. Shestakova, et al.
Publicado: (2021)